Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| M, R, H | WB | Rb | Affinity Purified | Polyclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | AB15322 |
| Description | Anti-Nicotinic Acetylcholine Receptor α4 Antibody |
| Alternate Names |
|
| Background Information | Nicotinic acetylcholine receptors, or nAChRs, are cholinergic receptors that form ligand-gated ion channels in the plasma membranes of certain neurons. nAChR is triggered by the binding of the neurotransmitter acetylcholine (ACh) and is also opened by nicotine. After binding ACh, the nAChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. nAChRs are present in many tissues in the body: the neuronal receptors are present in the central nervous system and the peripheral nervous system; and the neuromuscular receptors are found in the neuromuscular junctions of somatic muscles. Neuronal AChR is composed of two different types of subunits: alpha (α) and beta (β). |
| Product Information | |
|---|---|
| Format | Affinity Purified |
| Control |
|
| Presentation | Rabbit purified polyclonal serum in buffer containing 0.1 M Tris-Glycine (pH7.4) 150 mM NaCl with 0.05% sodium azide. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Detect Nicotinic Acetylcholine Receptor α4 using this Anti-Nicotinic Acetylcholine Receptor α4 Antibody validated for use in WB. |
| Key Applications |
|
| Biological Information | |
|---|---|
| Immunogen | This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from residues of Nicotinic Acetylcholine Receptor α4. |
| Epitope | Extracellular Domain |
| Concentration | Please refer to the Certificate of Analysis for the lot-specific concentration. |
| Host | Rabbit |
| Specificity | This antibody recognizes Nicotinic Acetylcholine Receptor α4. |
| Species Reactivity |
|
| Antibody Type | Polyclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | Nicotinic acetylcholine receptor subunit responsible for binding calcium sensor protein visinin-like protein-1 (Vilip1), which modulates acetylcholine receptor expression and sensitivity [RGD]. |
| Gene Symbol |
|
| Modifications |
|
| Purification Method | Antigen Affinity Purified |
| UniProt Number |
|
| UniProt Summary | "FUNCTION: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. SUBUNIT STRUCTURE: Pentamer of two alpha chains, and one each of the beta, delta, and gamma (in immature muscle) or epsilon (in mature muscle) chains. SUBCELLULAR LOCATION: Cell junction › synapse › postsynaptic cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein. TISSUE SPECIFICITY: Isoform 1 is only expressed in skeletal muscle whereas isoform 2 is constitutively expressed in skeletal muscle, brain, heart, kidney, liver, lung and thymus. INVOLVEMENT IN DISEASE: Defects in CHRNA1 are a cause of lethal type multiple pterygium syndrome [MIM:253290]. Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent. The alpha subunit is the main focus for antibody binding in myasthenia gravis [MIM:254200]. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs. Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes. Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS) [MIM:608930]. FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential. SEQUENCE SIMILARITIES: Belongs to the ligand-gated ionic channel (TC 1.A.9) family. [View classification] |
| Molecular Weight | Approx. 55 kDa |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Evaluated by Western Blot in rat e16 brain lysate. Western Blot Analysis: : 1:1,000 dilution of this lot detected Nicotinic Acetylcholine Receptor α4 in 10 µg of e16 rat brain lysate. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Maintain refrigerated at 2-8°C for up to 12 months from date of receipt. |
| Packaging Information | |
|---|---|
| Material Size | 100 µg |